Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival
暂无分享,去创建一个
G. Morgan | W. Gregory | W. Tapper | B. Walker | F. Ross | F. Davies | G. Jackson | J. Child | C. Wardell | Z. Konn | L. Chiecchio | K. Boyd | G. Dagrada | B. Walker
[1] G. Morgan,et al. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial , 2011, Leukemia.
[2] G. Morgan,et al. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide‐based therapy , 2011, Genes, chromosomes & cancer.
[3] G. Morgan,et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. , 2011, Blood.
[4] Trevor J Pugh,et al. Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.
[5] Fiona M Ross,et al. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. , 2011, Blood.
[6] G. Morgan,et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial , 2010, The Lancet.
[7] G. Morgan,et al. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. , 2010, Blood.
[8] G. Morgan,et al. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance , 2010, Haematologica.
[9] J. Carpten,et al. Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma , 2010, Leukemia.
[10] G. Morgan,et al. Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome , 2010, Clinical Cancer Research.
[11] N. Cross,et al. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context , 2009, Haematologica.
[12] B. Barlogie,et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review , 2009, Leukemia.
[13] G. Morgan,et al. Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications , 2008, Clinical Cancer Research.
[14] G. Morgan,et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. , 2007, Blood.
[15] Michael L. Wang,et al. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[16] R. Bataille,et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.
[17] P. Sonneveld,et al. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high‐dose chemotherapy in patients with multiple myeloma , 2007, British journal of haematology.
[18] F. Zhan,et al. Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression , 2006, Cell Division.
[19] Cheng Li,et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. , 2006, Blood.
[20] Yongsheng Huang,et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. , 2006, Blood.
[21] G. Morgan,et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma , 2006, Leukemia.
[22] P. L. Bergsagel,et al. Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Rue,et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.